UPDATE: Juniper to Buy Theragenics at $2.20/Share in Cash

Theragenics Corporation^® TGX (the “Company”), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it has signed a definitive merger agreement pursuant to which a newly formed affiliate (the “Purchaser”) of Juniper Investment Company, LLC will acquire all of the outstanding common stock of the Company for $2.20 per share in cash. The Board of Directors of the Company unanimously approved the merger agreement and the transactions contemplated thereby. The merger agreement permits the Company to solicit competing offers from credible and bona fide third parties through September 6, 2013.